Background: The cytotoxic effect of chemotherapeutic agents to the oral mucosa,
Background: The cytotoxic effect of chemotherapeutic agents to the oral mucosa, as a side effect of cancer treatment, is a major problem. Cooling the oral mucosa using ice chips in conjunction with chemotherapy is known to reduce the severity of oral mucositis. However, although the use of ice chips is of clinical value, this method of cooling has inherent problems including discomfort for the patient, nonuniformity and fluctuations in cooling temperature throughout the oral cavity. Furthermore, despite being used clinically, it is not known what reduction in temperature is required to prevent oral mucositis. The aim of this study was therefore to determine in vitro if the cytotoxic effect of 5-fluorouracil (5-FU) on the oral mucosa could be reduced by lowering the temperature during chemotherapeutic treatment.
Methods: Tissue-engineered oral mucosal (TEOM) models were incubated at 20, 25, 30 or 35°C for 30 minutes followed by exposure to a clinically relevant concentration of 5-FU (162 lg/mL) for 2 hours and compared with untreated models (35°C). Cell viability and inflammatory cytokine production (IL-6 and TNF-a) were measured using PrestoBlue â and ELISA, respectively.
Results: TEOM models incubated at 20°C showed an increased cell viability and had a reduced IL-6 and TNF-a production compared to models treated with 5-FU incubated at 35°C.
Conclusion:
This study demonstrates a reduced cytotoxic effect to the TEOM by reducing the temperature of the tissue during chemotherapy treatment and suggests that decreasing the temperature to 20°C could have clinical advantages.
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| INTRODUCTION
Chemotherapy, along with radiotherapy and surgery, is the most commonly used strategy to treat cancer. 1 The main action of chemotherapy is to target rapidly dividing cells, which is a characteristic feature of cancer cells. 2 However, oral epithelial cells are also highly proliferative 3 and are therefore susceptible to the cytotoxic effect of chemotherapeutic agents. 4 5-Fluorouracil (5-FU) is a well-established chemotherapeutic drug and has for a long time been used for the management of a range of different cancers including colorectal, breast and skin cancer, but is also an alternative treatment in patients with metastatic or recurrent head and neck cancer. 5-FU is an analogue of uracil and enters the cells through the same facilitated transport mechanism as the nucleotide. Intracellularly, 5-FU is converted to several active metabolites that are further incorporated into macromolecules such as DNA and RNA, inhibiting their normal functions.
5-7
The mechanism by which chemo-and radiation therapy induce cell damage is believed to arise from of a cascade of biological events taking place in the underlying subepithelium. Subsequent activation of transcription factors and release of several pro-inflammatory cytokines, including IL-6 and TNF-a, in turn leads to a compromised mucosal lining and ulcerations known as mucositis. 8 Mucositis is common debilitating side effect following chemotherapy and is frequently seen in clinical settings prior to hematopoietic stem cell transplantation. 9 It affects the lining epithelium of the entire oral and gastrointestinal tract 10 and in its mildest form manifests clinically as an erythematous lesion. However, in more severe forms, painful ulceration caused by epithelial detachment from the underlying submucosa is observed and routinely necessitates narcotic analgesia. 11 Mucositis may also interfere with food and liquid intake and have a negative impact on several aspects of quality of life (emotional, social and functional).
12,13
Chewing on ice chips before and during chemotherapy infusion is currently the standard approach for prevention of oral mucositis.
14 However, ice chips are extremely cold upon first exposure in the oral cavity causing discomfort including headache and teeth sensations. 15 In addition, the intraoral temperature during ice chip treatment is not constantly maintained and declines rapidly, therefore providing only transient benefit to the patient. The aim of this study was to determine whether cooling, using a constant low temperature, 
| Production of TEOM models
Tissue-engineered oral mucosal models were produced as previously described. 16 Briefly, de-epithelized dermis (1 cm 2 ) was placed in each well of a 6-well plates, an 8-mm-diameter steel ring laid on the upper surface and 5 9 10 5 NOFs and 1 9 10 6 NOKs added in 500 lL of Green's medium. Medium was changed twice daily for 48 hours at which point the rings were removed and the models incubated at an air-to-liquid interface on steel grids for a further 10 days at 37°C, 5% CO 2 .
| Drug treatments
To determine the optimum drug concentration, TEOM models were treated with 2 mL of 5-FU, dissolved in Green's media, at 3 different clinically relevant concentrations (54, 162 and 324 lg/mL) along with a control (no drug applied) and SDS-treated (1%) control for 2 hours. Following the incubation, TEOM models were rinsed in prewarmed (37°C) PBS to eliminate superficial cytostatics and replaced with pre-warmed (37°C) medium. Models were incubated for a further 30 minutes at 37°C, washed again with PBS to eliminate profound cytostatics, replaced with fresh medium and incubated for 48 hours at 37°C before analysis.
| Temperature effects on TEOM
Based on initial experiments, it was determined that a 5-FU concentration of 162 lg/mL would enable the effects of temperature to be assessed in the TEOM models. TEOM models were pre-incubated at 20, 25, 30 or 35°C for 30 minutes before treatment with 5-FU (162 lg/mL) for 2 hours or at 35°C with no drug used as a control.
Following the incubation, TEOM models were rinsed in PBS at the specified temperatures to eliminate superficial cytostatics and replaced with fresh medium. Models were incubated for a further 30 minutes at the specified temperatures, washed again with PBS to eliminate profound cytostatics, replaced with fresh medium and incubated for 48 hours at 37°C before analysis.
| Cell viability assay
To measure cell viability, PrestoBlue â (Thermo Fisher, Massachusetts, USA) was used according to the manufacturer's instructions. Briefly, TEOM models were immersed in 1. were normalized relative to the control (0 lg/mL 5-FU), which was set at 1.
| Enzyme-linked immunosorbent assay
Commercially available ELISA (OptEIA TM , BD Bioscience) kits were used according to the manufacturer's instructions to measure levels of IL-6 and TNF-a in TEOM conditioned medium as described previously. 17 
| Histological analysis
For histological analysis, TEOM models were removed from the culture medium, washed with PBS and fixed in 10% buffered formalin overnight. The model was bisected and subjected to routine histological processing and then paraffin wax embedded. Five micrometre sections was cut using a Leica RM2235 microtome (Leica microsystems) and stained with haematoxylin and eosin (H&E).
| Statistics
Data are presented as mean AE standard deviation (SD) of 3 independent experiments (n = 3) with each test performed in triplicate unless otherwise stated. ANOVA (one-way ANOVA and Dunnett's multiple hypothesis correction) multiple statistical comparisons were performed using GraphPad Prism v6.00 (GraphPad Software, La Jolla, CA, USA) and differences between test and control groups considered significant when P < .05.
| RESULTS
An initial drug dose-response was performed to determine the optimum concentration of 5-FU needed to reduce cell viability in fullthickness TEOM to subsequently enable the investigation of a cooling effect during drug treatment on cell viability and cytokine release. Cell viability was measured after a 48-hours incubation following a 2-hours treatment with 54, 162 or 324 lg/mL 5-FU. A dose-response effect was observed with 5-FU at a concentration of 54 lg/mL having no effect on TEOM model viability but the higher concentrations (162 and 324 lg/mL) causing a statistically significant decrease in viability with an overall reduction of 36% (P < .001) and 28% (P < .05), respectively ( Figure 1A ). Following the same trend, an increase in TNF-a production was observed for the higher concentrations of 5-FU (162 or 324 lg/mL) tested following a 2-hours incubation, although these did not reach significance from the untreated control ( Figure 1B) . Based on these results, a drug concentration of 162 lg/mL was used for all further experiments.
To investigate the effect of cooling on cell viability, TEOM models were treated with 5-FU (162 lg/mL) for 2 hours at 20, 
| DISCUSSION
Oral mucositis affects approximately 80% of all cancer patients treated with high doses of chemotherapy prior to stem cell transplantation. 18 Cooling the oral mucosa using ice chips has been demonstrated to reduce the risk and severity of oral mucositis. 19, 20 The presumed protective mechanism of reducing the temperature of the oral mucosa is believed to be a local vasoconstriction resulting in a reduced drug delivery to the epithelial cells as well as lowered metabolic activity in the basal layer, making the epithelium less susceptible to cytotoxic agents. 19 The TEOM is a composite model of oral epithelial cells and oral fibroblasts cultured on a decellularized dermal scaffold and enables in vitro investigations in a relevant physiological environment. 21 Although being the best in vitro model for the purpose of this study, it does not completely replicate the complex structure of the oral mucosa seen in vivo. 8 In particular, the model lacks immune cells and blood vessels, which prevents the possibility of studying the importance of vasoconstriction. Based on these limitations, our findings are most likely attributed to lowered metabolic activity to explain the prevention of irreversible cell damage after exposure to chemotherapeutic agents. Furthermore, considering the absence of essential immune components the models used in this particular experiment may not reflect the immune response in its entirety that is observed in vivo.
Pre-incubation temperatures for the TEOM models were selected based on 2 separate studies on healthy volunteers where an approximate mean temperature of 25-30°C was obtained in the oral mucosa. 22, 23 These temperatures were further selected with an interval of 5°C as they represented clinically relevant temperatures.
The decision to use 5-FU was based on the fact that it is one of the most commonly used chemotherapeutic drugs in clinical oncologic practice. 7 5-FU has several known adverse effects such as
The effects of cooling on tissue-engineered oral mucosa model IL-6 secretion. Tissue-engineered oral mucosa model IL-6 secretion was measured 48 h post-incubation following treatment with 5-FU (162 lg/mL) for 2 h at different cooling temperatures (20, 25, 30 and 35°C) compared with untreated controls (35°C). Data are presented as mean AE standard deviation (n = 3)
The effects of cooling on tissue-engineered oral mucosa model TNF-a production. Tissue-engineered oral mucosa model TNF-a production was measured 48 h post-incubation following treatment with 5-FU (162 lg/mL) for 2 h at different cooling temperatures (20, 25, 30 and 35°C) compared with untreated controls (35°C). Data are presented as mean AE standard deviation (n = 3), *P ≤ .05, **P ≤ .01 gastrointestinal and oral mucositis, which is a major complication. 24 Furthermore, it has been demonstrated that 5-FU induces an inflammatory response, including the production of the pro-inflammatory cytokines IL-6 and TNF-a in animal models, 25 cytokines that were investigated in this in vitro study.
Mucositis is described as a complex biological process that occurs as a result of a series of interactions, including the activation of the transcription factor nuclear factor-kappa B (NF-jB) and release of pro-inflammatory cytokines, for example IL-6 and TNF-a. 8 Previous studies have shown an increase in expression of such factors in experimental models of anticancer treatment. 21, 26, 27 In accordance with the findings of these previous studies, we found that TEOM models exposed to 5-FU expressed pro-inflammatory cytokines to a greater extent than untreated controls. In our previous study, we did not detect expression of TNF-a in an in vitro model of radiation-induced mucositis, 21 whereas levels of TNF-a were This study demonstrated that TEOM models incubated with 5-FU at lower temperatures had an improved ability to preserve their cell viability compared with models incubated at higher temperatures. The reverse temperature-dependent pattern was seen for IL-6 production, and the pattern was even more obvious for TNF-a expression, as treated models incubated at lower temperatures had significantly lower production of pro-inflammatory cytokines. This was particularly true in models incubated at 20°C compared with those incubated at 35°C. These results are consistent with previous clinical reports showing that cooling has a protective effect on mucosa exposed to chemotherapeutic agents. 19, 20 In contrast to the extensive epithelial damage caused in radiated TEOM models, the histological examination of TEOM models | 481 difficult to state if a correlation exists between preservation of the integrity of epithelial and incubation at lower temperatures in TEOM models exposed to 5-FU as models were followed only for 48 hours.
However, based on our histological examination, no such correlation exists. Further studies with longer follow-up periods are needed to investigate whether a true correlation exists. Furthermore, it would be of interest to study the model's biological mechanism and its cellular response to 5-FU as well as other chemotherapeutic agents when blood vessels and immune components are incorporated in the model. Partly because these are key components in the pathobiology of the immune system but in particular to further mimic the physiology of the oral mucosa seen in vivo.
An example of other chemotherapeutic agents that could have been used and evaluated in this study is Melphalan, a bifunctional alkylating agent that does not require metabolic activation. Similar to 5-FU, it incorporates into macromolecules, but instead Melphalan exerts its effects through DNA interstrand cross-linking, which leads to replication arrest and cell death. 30 In summary, this is the first study to evaluate the cytotoxic effect of a chemotherapeutic agent on oral mucosa in vitro and also the first in vitro study to investigate whether the cytotoxic effect could be reduced by lowering the temperature. Our findings show that models incubated at lower temperatures have a higher cell viability and reduced cytokine production and further suggest that decreasing oral mucosal temperature to 20°C in conjunction with chemotherapy could have clinical advantages.
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